Share :

partage facebook
partage twitter
partage linkedin

Stemming from the world of blood transfusion and privileged partner of EFS (French Blood service), DIAGAST is now your legitimate partner in Immunohaematology since 1988.

Innovative transfusion solutions around the world


Our mission at the heart of health systems

Immunohaematology is an essential component of modern medicine, aiming to ensure total transfusion compatibility between blood donors and patients. For effective, safe transfusions, it is vital to ensure that each patient is protected from any possible risk of error. 

This responsibility is always uppermost in our minds. Our primary objective has not changed since our company was created: to provide healthcare players with a high-performance, safe range of products and services capable of guaranteeing the highest levels of compatibility between donors and recipients. 

Because receiving blood means receiving life.


Immunohaematology: a public health issue

For more than thirty years, we have been supplying laboratories and blood transfusion centres worldwide with state-of-the-art reagents and automated systems to determine blood groups, a task which is vitally important in ensuring maximum transfusion safety. 

Working at the intersection of haematology and immunology, we design, develop, manufacture and market reliable, appropriate, fast and efficient tools and services for use by health professionals worldwide.

Our specific skills derive from unparalleled cell assets including more than 40 clones, and the large production capacity offered by our wide range of fermenters at our Eurasanté site. This acknowledged industrial excellence means that we are able to supply all of our customers: laboratories, hospitals, clinics, transfusion centres, NGOs, major global manufacturers of diagnostics, etc.

Our comprehensive technical solutions, tailored to each customer in accordance with their local needs, incorporate user support and training, and also constant monitoring and assistance.


Inheritors of a distinctively French skillset

Prior to its official establishment in 1988, DIAGAST was developed as a laboratory within the city of Lille’s Regional Blood Transfusion Centre. It was here that an extensive range of revolutionary monoclonal reagents was developed, with Diagast taking responsibility for their development and marketing. As a subsidiary of the Établissement Français du Sang (EFS) blood transfusion organisation, which enjoys an international reputation for its know-how and skills, we work hand in hand with it to implement complementary approaches: the EFS deals with practical transfusion arrangements and DIAGAST handles industrial activity.

The milestones in pictures

DIAGAST MILESTONES

1968 - THE VERY BEGINNING
Sale of polyclonal sera for blood grouping.
1984 - INNOVATION BECAME A TRUE "TRADEMARK
Start of production of monoclonal antibodies in fermentors at the Lille's Regional Transfusion Center.
1988 - DIAGAST IS HENCEFORTH A STANDALONE COMPANY
Creation of DIAGAST with the industrial production of monoclonal antibodies.
1997 - FIRST STEP IN CERTIFICATION
ISO 9001-1994 Certification.
2003 - STRONG COMMITMENT TO QUALITY ASSURANCE SINCE 1997
ISO 9001:2000, ISO 13485:2001 and EC Marking.
2004 - MAGNETIC ATTRACTION OF A BRAND NEW TECHNOLOGY
Launch of EM®Technology, a new technology based on the RBC's magnetization.
2005 - CREATION OF A SUBSIDIARY IN SPAIN
DIAGAST Iberica is born.
2008 - ON THE ROAD TO NEW MARKETS IN NORTH AMERICA
FDA approval received in the USA and supply of reagents used in American blood banks.
2009 - QWALYS® 3: A NEW ERA OF ABSOLUTE PERFORMANCE
Third generation of  QWALYS®.
2010 - DIAGAST IS BRANCHING OUT INTO THE ASIAN MARKETS
Subsidiary opened in India: DIAGAST India.
2012 - M-TRAP®: A COMPLETE BREAKTHROUGH VS THE EXISTING TECHNOLOGIES
Launch of M-TRAP®, a new technology for determining blood groups, and a new bedside card ABTest Card®.
2014 - FIRST STRATEGIC ACQUISITION FOR DIAGAST
Takeover of the start-up ABODiag and acquisition of new patents.
2016 - LAUNCH OF ABD PAD®
An innovative IVDMD for the confirmation of manual blood group, in 3 steps and 30 seconds.
2017 - QWALYS 3® EVO   WHEN QWALYS® IS REINVENTING ITSELF
A STAT function, a dynamic scheduler and a new user interface: 3 news features that make the difference.
2019 - NEW INDUSTRIAL PREMISES
It doubles our production capacities and provides an industrial resource offering the highest levels of performance